Last Updated: 10 Nov 2024
Executive Summary
Alkermes Plc (ALKS) is a biopharmaceutical company with a market capitalization of $4.67 billion. The company has a strong financial position with an EBITDA of $358.8 million and a trailing PE ratio of 12.6. Alkermes is expected to continue to grow in the future, with analysts forecasting a target price of $33.46.
Company Overview
Alkermes Plc is a biopharmaceutical company that researches, develops, and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas. The company's products include treatments for schizophrenia, bipolar disorder, depression, and addiction. Alkermes is headquartered in Dublin, Ireland, and has operations in the United States, Europe, and Asia.
Fundamental Analysis
Alkermes Plc has a strong financial position. The company's revenue has grown steadily in recent years, and its profitability has improved. Alkermes has a strong balance sheet with low debt and ample cash flow. The company's trailing PE ratio of 12.6 is attractive relative to its peers.
Technical Analysis
Alkermes Plc's stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also trending higher, indicating that the stock is in a bullish trend.
Short Term Outlook
Alkermes Plc's stock is expected to continue to perform well in the short term. The company's strong financial position and positive analyst sentiment are likely to support the stock price. The stock's technical indicators also suggest that the stock is in a bullish trend.
Long Term Outlook
Alkermes Plc is expected to continue to grow in the long term. The company's pipeline of new products is expected to drive growth in the coming years. The company's strong financial position and experienced management team are also likely to contribute to the company's long-term success.
Analyst Recommendations
Analysts are bullish on Alkermes Plc. The consensus analyst rating is "buy." The average analyst target price is $33.46.
